Overall Status

Completed (2)

Recruiting (1)

Unknown status (1)

Phase

phase 2 (2)

n/a (1)

phase 4 (1)

Sponsor

Novartis Pharmaceuticals (2)

Seoul St. Mary's Hospital (1)

Shenzhen Second People's Hospital (1)

Collaborator

Dongguan People's Hospital (1)

First Affiliated Hospital of Shantou University Medical Collegeity (1)

Hainan General Hospital (1)

Ministry of Health & Welfare, Korea (1)

Peking University Shenzhen Hospital (1)

Sanya Central Hospital (1)

Intervention

flumatinib (1)

high-dose imatinib (1)

imatinib treatment discontinuing (1)

sti571 (glivec®) (1)

Study Documents

Intervention Type

drug (3)

behavioral (1)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (4)

imatinib

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting

Flumatinib
+2 more

Flumatinib

Shenzhen, Guangdong, China

The Second People's Hospital of Shenzhen

Mar 15, 2022

CML, Imatinib Trial in Seoul (high-dose imatinib)

Completed

CML
Imatinib

high-dose imatinib

Seoul, Korea, Republic of

Novartis Investigational Site

Mar 9, 2021

Prostatic Tumor, Genital Tumors, Male, Tumors, Abdominal Trial in Germany (STI571 (Glivec®))

Completed

Prostatic Neoplasm
+7 more

STI571 (Glivec®)

Aachen, Germany
+12 more

May 31, 2017

Chronic Myeloid Leukemia, Imatinib, Complete Molecular Response Trial in Seoul (Imatinib treatment discontinuing)

Unknown status

Chronic Myeloid Leukemia
+2 more

Imatinib treatment discontinuing

Seoul, Korea, Republic of
+1 more

Jan 10, 2014